PLX-492 / Plexium - LARVOL DELTA

Preclinical characterization of SMARCA2-selective monovalent direct degraders (EORTC-NCI-AACR 2024) - "SMARCA2 degraders had no impact on tumor growth using a SMARCA4WT xenograft model, supporting the dependency of SMARCA4 mutational status for SMARCA2-selective degrader efficacy. These results highlight the discovery and development of novel potent, selective, and orally bioavailable SMARCA2 monovalent direct degraders. The preclinical characterization of our degraders demonstrates their activity and potential utility in the treatment of SMARCA4MUT solid tumors."

Preclinical • Oncology • Solid Tumor • SMARCA2 • SMARCA4